Eli Lilly shares rose Thursday after the drugmaker's adjusted profit came in above estimates, offsetting weaker-than-expected revenue.

Eli Lilly expects to read out results from a study in people with obesity and osteoarthritis of the knee in 2025.

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks on Jim Cramer's radar. Jim Cramer, host of Mad Money, shared his thoughts on ...

Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 ...

Booming sales of its blockbuster incretin-based weight loss and diabetes drugs Mounjaro and Zepbound powered Eli Lilly (LLY) to a 45% jump in ...

We recently compiled a list of the 7 Stocks on Jim Cramer’s Radar. In this article, we are going to take a look at where Eli ...

Eli Lilly ripped off the bandage when it reported preliminary fourth-quarter results in mid-January, getting the bad news out ...

In this article, we are going to take a look at where Eli Lilly and Company (NYSE:LLY) stands against the other stocks Jim Cramer recently discussed. Jim Cramer's appearance on Squawk on the ...

We recently compiled a list of the 12 Best Long Term Low Risk Stocks to Buy Right Now. In this article, we are going to take ...

I think Eli Lilly and ... production expansion and new drug launches to drive future growth and support valuation. The end-market's slowdown, as well as the company's reduced sales guidance ...

I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly ... But every other drug company is operating in that ...